GlassScriptPhysician profile
Ilya Shneyderman
NPI 1265428528
$2,137.59
in general payments reported to CMS, 2019-2025
14 companies · $209 in 2025
The $209 reported for 2025 was less than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
See the full distribution for Nephrology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $196 · 2020: $410 · 2021: $493 · 2022: $282 · 2023: $363 · 2024: $184 · 2025: $209.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $756.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $755.96 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $961.22 | 2019-2024 | Lokelma, Farxiga |
| Vifor Pharma, INC. | $356.58 | 2019-2024 | Veltassa, Korsuva |
| Akebia Therapeutics INC | $337.15 | 2019-2025 | Vafseo, Auryxia |
| Alexion Pharmaceuticals, INC. | $112.00 | 2020 | |
| Aurinia Pharma U.S., INC. | $68.96 | 2022-2023 | Lupkynis |
| Glaxosmithkline, LLC. | $68.84 | 2021-2022 | |
| Amgen INC. | $38.16 | 2019-2020 | |
| Fresenius USA Marketing, INC. | $33.61 | 2019-2022 | |
| Apellis Pharmaceuticals, INC. | $32.95 | 2025 | Empaveli |
| Bard Peripheral Vascular, INC. | $32.69 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $24.71 | 2024 | Nulojix |
| Calliditas Therapeutics US INC. | $24.13 | 2024 | |
| Urogen Pharma, INC. | $23.69 | 2025 | |
| Otsuka America Pharmaceutical, INC. | $22.90 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ilya Shneyderman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.